Billard-Sandu Camelia, Cabulca Andreea, Rassy Elie, Dumitrescu Gabriela, Akla Sarah, Assi Tarek, Zeghondy Jean, Blanchard Pierre, Tao Yun Gan, Nguyen France, Sun Roger, Scotte Florian, Puglissi Vanessa, Di Palma Mario, Breuskin Ingrid, Temam Stephane, Deutsch Eric
Department of Radiation Oncology, Gustave Roussy, 114 Rue Edouard Vaillant, R94805, Villejuif, France.
Departement of Medical Oncology, Gustave Roussy, Villejuif, France.
Support Care Cancer. 2025 Jun 3;33(6):530. doi: 10.1007/s00520-025-09597-1.
High-dose cisplatin (100 mg/m every 3 weeks for three cycles), administered with radiotherapy for locally advanced head and neck cancer, is associated with acute kidney injury (AKI) in up to 30% of patients and may compromise treatment intensity in 20%.
To assess the impact of a 1-week at-home hydration protocol following each cisplatin cycle on treatment tolerance and chemotherapy dose intensity.
We conducted a retrospective analysis of patients with locally advanced head and neck cancer treated at Gustave Roussy between January 2015 and December 2020. Eligible patients received at least one cycle of high-dose cisplatin (100 mg/m) with radiotherapy. The institutional hydration protocol included a 3-day hospital stay with intensive intravenous hydration, followed by at-home administration of 0.9% sodium chloride (1 L/12 h) for 1 week after each cycle.
A total of 494 patients were included; 470 (95%) were under 70 years old. Of these, 451 (91%) received at least 200 mg/m of cisplatin, and 242 (49%) completed the full 300 mg/m dose (median cumulative dose: 280 mg/m). AKI of any grade occurred in 117 patients (24%), including 14 (3%) with Grade 3 toxicity. Dose reductions were necessary in 252 patients, primarily due to mucositis/vomiting (12%), myelosuppression (11%) or AKI (8%), CONCLUSION: A 1-week at-home hydration protocol was associated with lower nephrotoxicity and higher chemotherapy dose intensity than historically reported. This strategy appears to be an effective supportive care measure to optimize high-dose cisplatin administration.
高剂量顺铂(每3周100mg/m²,共三个周期)联合放疗用于局部晚期头颈癌治疗时,高达30%的患者会发生急性肾损伤(AKI),且20%的患者治疗强度可能会受到影响。
评估每个顺铂周期后为期1周的家庭水化方案对治疗耐受性和化疗剂量强度的影响。
我们对2015年1月至2020年12月在古斯塔夫·鲁西研究所接受治疗的局部晚期头颈癌患者进行了回顾性分析。符合条件的患者接受了至少一个周期的高剂量顺铂(100mg/m²)联合放疗。机构水化方案包括住院3天进行强化静脉水化,然后在每个周期后在家中给予0.9%氯化钠(1L/12小时),持续1周。
共纳入494例患者;470例(95%)年龄在70岁以下。其中,451例(91%)接受了至少200mg/m²的顺铂,242例(49%)完成了全部300mg/m²的剂量(中位累积剂量:280mg/m²)。117例患者(24%)发生了任何级别的AKI,包括14例(3%)3级毒性反应。252例患者需要降低剂量,主要原因是粘膜炎/呕吐(12%)、骨髓抑制(11%)或AKI(8%)。
与既往报道相比,为期1周的家庭水化方案肾毒性较低,化疗剂量强度较高。该策略似乎是优化高剂量顺铂给药的有效支持性护理措施。